Claudia María Valverde Morales, MD, Vall d’Hebron University Hospital, Barcelona, Spain, comments on the feasibility of tumor agnostic approaches for rarer cancers and how this challenge can be tackled in the context of clinical trial design. Dr Valverde Morales recognizes that although it can be difficult to perform randomized clinical trials with a large sample size, basket trials may serve as the next best solution to this issue. These trials may be designed with inclusion criteria that are based on specific genetic alterations the patient has rather than the subtype of cancer they have been diagnosed with. This interview took place at the ESMO Sarcoma and Rare Cancers Congress 2023 in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
